Table of Contents
<< Previous Issue | Apr 2021 (Vol: 2021, Issue: 4) | Next Issue >> |
- Section: Licensing
-
Merck KGaA Expands Head and Neck Cancer Therapy Portfolio with Debiopharm’s Xevinapant
-
Pfizer Pledges up to US$4.4 B for Myovant’s Orgovyx
- Section: Mergers & Acquisitions
-
Roche Advances Infectious Disease Diagnostic Portfolio with US$1.8 B GenMark Acquisition
-
Eli Lilly Acquires Gene Therapy Company Prevail Therapeutics for US$1.04 B
- Section: Research & Development
-
Helsinn Boosts Oncology Portfolio with BridgeBio’s Infigratinib
-
Janssen Ups Influenza Investment with US$780 M Bet on Cidara’s AVC Platform